Evropská unie -
norština -
EMA (European Medicines Agency)
imbruvica
janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.
Norsko -
norština -
Statens legemiddelverk
venclyxto 10 mg
abacus medicine a/s - venetoklaks - tablett, filmdrasjert - 10 mg
Norsko -
norština -
Statens legemiddelverk
venclyxto 50 mg
abacus medicine a/s - venetoklaks - tablett, filmdrasjert - 50 mg
Norsko -
norština -
Statens legemiddelverk
venclyxto 100 mg
abacus medicine a/s - venetoklaks - tablett, filmdrasjert - 100 mg
Norsko -
norština -
Statens legemiddelverk
bendamustine accord 2.5 mg/ ml
accord healthcare b.v. - bendamustinhydrokloridmonohydrat - pulver til konsentrat til infusjonsvæske, oppløsning - 2.5 mg/ ml
Norsko -
norština -
Statens legemiddelverk
levact 2.5 mg/ ml
astellas pharma gmbh (1) - bendamustinhydroklorid - pulver til konsentrat til infusjonsvæske, oppløsning - 2.5 mg/ ml
Evropská unie -
norština -
EMA (European Medicines Agency)
polivy
roche registration gmbh - polatuzumab vedotin - lymfom, b-celle - antineoplastiske midler - polivy i kombinasjon med bendamustine og rituximab er indisert for behandling av voksne pasienter med tilbakefall/ildfast diffuse store b-celle lymfom (dlbcl) som ikke er kandidater for haematopoietic stamcelletransplantasjon. polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (r-chp) is indicated for the treatment of adult patients with previously untreated diffuse large b-cell lymphoma (dlbcl).